VYNE Therapeutics (NASDAQ:VYNE) Announces Earnings Results, Beats Estimates By $0.03 EPS

VYNE Therapeutics (NASDAQ:VYNE) announced its earnings results on Thursday. The company reported ($0.28) EPS for the quarter, beating analysts’ consensus estimates of ($0.31) by $0.03, Zacks reports. VYNE Therapeutics had a negative return on equity of 43.73% and a negative net margin of 6,896.55%. The company had revenue of $0.08 million during the quarter, compared to analysts’ expectations of $0.14 million.

VYNE Therapeutics Stock Performance

Shares of NASDAQ VYNE opened at $2.19 on Friday. VYNE Therapeutics has a fifty-two week low of $1.57 and a fifty-two week high of $4.30. The firm has a market capitalization of $32.30 million, a PE ratio of -2.55 and a beta of 1.13. The stock’s 50-day simple moving average is $2.76 and its 200-day simple moving average is $2.50.

Insider Transactions at VYNE Therapeutics

In other VYNE Therapeutics news, Director Patrick G. Lepore bought 15,000 shares of the business’s stock in a transaction dated Wednesday, January 15th. The shares were acquired at an average price of $2.92 per share, with a total value of $43,800.00. Following the transaction, the director now owns 51,472 shares of the company’s stock, valued at approximately $150,298.24. The trade was a 41.13 % increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which can be accessed through the SEC website. Corporate insiders own 4.80% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities analysts recently commented on the company. BTIG Research assumed coverage on VYNE Therapeutics in a report on Monday, November 18th. They set a “buy” rating and a $8.00 target price for the company. HC Wainwright reiterated a “buy” rating and issued a $5.75 price objective on shares of VYNE Therapeutics in a research note on Thursday.

VYNE Therapeutics Company Profile

VYNE Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing proprietary and therapeutics for the treatment of immuno-inflammatory conditions. The company's lead product is VYN201, a locally administered pan- bromodomain and extra-terminal (BET) inhibitor soft drug to address diseases involving multiple, diverse inflammatory cell signaling pathways with low systemic exposure.